# Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

> **NCT01961115** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Mucosal Melanoma
- Recurrent Melanoma
- Recurrent Uveal Melanoma
- Stage IIIA Skin Melanoma
- Stage IIIA Uveal Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIB Uveal Melanoma
- Stage IIIC Skin Melanoma
- Stage IIIC Uveal Melanoma
- Stage IV Skin Melanoma
- Stage IV Uveal Melanoma

## Interventions

- **DRUG:** Epacadostat
- **BIOLOGICAL:** MELITAC 12.1 Peptide Vaccine

## Key facts

- **NCT ID:** NCT01961115
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-13
- **Primary completion:** 2016-10-31
- **Final completion:** 2017-05-18
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01961115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01961115, "Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01961115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*